Proteins and Peptides

09 Jul 2020 Croma-Pharma announces submission for their botulinum toxin to treat glabellar (frown) lines to the German authority BfArM
08 Jul 2020 NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
08 Jul 2020 Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment
07 Jul 2020 U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite
06 Jul 2020 EspeRare Receives FDA Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
06 Jul 2020 Insulin aspart Sanofi® receives EU marketing authorization, broadening options and increasing treatment choice for people with diabetes
01 Jul 2020 Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities
30 Jun 2020 Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet, Respectively
30 Jun 2020 Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns
29 Jun 2020 Teijin Receives Marketing Approval for Merz’s Xeomin® Botulinum Toxin Type A in Japan
28 Jun 2020 Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency
28 Jun 2020 Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog
26 Jun 2020 NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors
26 Jun 2020 Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
26 Jun 2020 Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU
24 Jun 2020 Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers
24 Jun 2020 Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System
24 Jun 2020 Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes
23 Jun 2020 Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020
23 Jun 2020 Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II
23 Jun 2020 Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II
23 Jun 2020 FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
22 Jun 2020 SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II
18 Jun 2020 Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity
18 Jun 2020 Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up